Emmis Acquisition (EMIS) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Emmis Acquisition is the larger company by market cap ($162.0 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | MENS |
|---|---|---|
| Share price | $10.27 | $2.10 |
| Market cap | $162.02M | $159.66M |
| 1-day change | 0.00% | +2.44% |
| YTD return | +3.22% | -46.84% |
| 1-year return | — | -95.89% |
| EPS (TTM) | — | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.27 | $63.00 |
| 52-week low | $9.90 | $1.43 |
| Distance from 52-week high | 0.00% | -96.67% |
| Average volume | 13.67K | 45.62K |
| Shares outstanding | 11.94M | 74.23M |
| Employees | — | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
EMIS vs MENS FAQ
Which is bigger, Emmis Acquisition or Jyong Biotech?
Emmis Acquisition (EMIS) is larger, with a market capitalization of $162.02M compared with $159.66M for Jyong Biotech (MENS).
Are Emmis Acquisition and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.